Vildagliptin

INN name:	Vildagliptin
Lab codes:	LAF-237; NVP-LAF237
Trade name:	GALVUS
Chemical name:	(2S)-{[(3-hydroxyadamantan-1-yl)amino]acetyl}pyrrolidine-2-carbonitrile
Molecular formula:	C17H25N3O2
Chemical Structure
CAS Registry Number	274901-16-5
Originator:	Novartis
Developer:	Hanmi Pharmaceutical; Novartis; UCB
Class:	Antihyperglycaemics; Biguanides; Cycloparaffins; Insulin sensitisers; Nitriles; Polycyclic bridged compounds; Pyrrolidines
Mechanism of Action:	AMP activated protein kinase stimulants; CD26 antigen inhibitors; Gluconeogenesis inhibitors; Glucose modulators
WHO ATC code:	A10B-D08 (Metformin and vildagliptin)
EPhMRA code:	A10J (Biguanide Antidiabetics) A10N (DPP-IV Inhibitor Antidiabetics)
US FDA approval:	No
Marketed:	Type 2 diabetes mellitus
Clinical Trials: Indication Phase Status Type 2 diabetes mellitus Phase 4 Completed Type 1 diabetes mellitus Phase 3 Completed Renal Impairment; Diabetes Phase 1/2 Completed Congestive Heart Failure; Type II Diabetes Mellitus Phase 4 Completed
Product Patent Expiry: USA December 2019 South Korea March 2022* Canada December 2019 China December 2019 Japan August 2024* * Patent expiry including patent term extension It is possible to extend the term of a patent in USA, KR and JP. The extension granted at the time of writing this post has been included and marked with *. Please leave a comment below for any update.
Sales of the product (Source: From company report): Years Sales* 2007 8 2008 43 2009 181 2010 391 2011 677 2012 910 2013 1200 2014 1244 *USD millions
Recent activities on the drug: